Safety of Anticoagulant Therapy After Endoscopic Treatment (NCT04976543) | Clinical Trial Compass
CompletedPhase 4
Safety of Anticoagulant Therapy After Endoscopic Treatment
China86 participantsStarted 2020-02-01
Plain-language summary
The investigators aimed to verify the efficacy and safety of nadroparin calcium warfarin sequential (NWS) anticoagulation therapy after endoscopic therapy in PVT patients with cirrhosis and AVB.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* clinical diagnosis of cirrhosis
* Portal hypertension with esophageal and gastric varices
* diagnosis of PVT by imaging examination
* undergo endoscopic therapy
Exclusion Criteria:
* older than 75 years
* uncontrolled active bleeding
* hepatocellular carcinoma or other extrahepatic malignancy
* on-going or received antithrombotic/thrombolytic treatment
* previous treatment with TIPSS
* cavernous transformation of the portal vein
* platelet count lower than 10\*10 \^ 9/L, creatinine more than 170 μmol/L
* Budd-Chiari syndrome
* pregnancy or breast-feeding period
* severe cardiopulmonary diseases, severe systemic infection or sepsis
* inability to sign informed consent